Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.


     Related Videos

     Related Hubpages

    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      Views: (3)   Date: (1994-10-1)   Pages: ()
    • Author:  J B Porter  

    • Abstract:  In order to identify new compounds which label platelets without affecting their function, three classes of metal chelating agents have been compared with oxine for their efficiency of indium-113m platelet labelling and for their short- and long-term effects on platelet function. The 3-hydroxypyridinones (both 2-ones and 4-ones) and 3-hydroxypyranones are bidentate chelators of trivalent metal ions that are neutrally charged in the metal-complexed form and hence gain access to cells readily. The hydroxypyranone ethylmaltol has been compared with the 3-hydroxypyridin-4-o ne CP94 and to its structurally related lipophilic analogue CP25 as well as with the 3-hydroxypyridin-2-o ne, CP02. The platelet labelling efficiencies with these ligands were between 75% and 95% of that obtained with oxine, following a 12-min incubation in saline. The optimal concentration for the hydroxypyridin-2-one s and hydroxypyridin-4-one s was approximately 10 microM compared with 100 microM for the hydroxypyranone ethylmaltol and 60 microM for oxine. Oxine and tropolone were found to produce significant inhibition of platelet aggregation to collagen in short-term experiments (10 min) or in longer term (18 and 42 h) ex vivo platelet cultures respectively. By contrast, ethylmaltol had no such inhibitory effects at either time interval. The relatively hydrophilic hydroxypyridin-4-one CP94 showed no inhibitory effects on collagen-induced aggregation in short-term studies, unlike the more lipid-soluble derivative CP25. These results suggest that ethylmaltol and related pyranones may have advantages over oxine and tropolone as indium platelet labelling agents where it is important not to damage platelets by the labelling process itself.

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

               Answers

               News
          • Study explains high platelets in ovarian cancer patients, survival reduced
            Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.
          • Drug helps maintain platelet inhibition and anti-clotting levels prior to cardiac surgery
            Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate of maintenance of platelet inhibition, compared to patients who received placebo, according to a study in the Jan. 18 issue of JAMA.
          • Platelet Rich Plasma Increasing in Popularity
            Tiger Woods, Kobe Bryant and Alex Rodriguez are among the elite athletes who have put PRP injections on the map. This treatment uses a patient's own blood to help heal sports injuries.
          • Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in Israel
            Cerus Corporation and Ilex BioTech Ltd. announced today that the INTERCEPT Blood System has received regulatory approval in Israel for the treatment of platelets and plasma intended for transfusion.
          • Thousand Oaks platelet donor meets teen recipient
            Ross Carmichael, 56, makes the drive from his Thousand Oaks home to the UCLA Blood and Platelet Center twice a month to donate platelets. On Friday, he got to meet a teen whose life he helped save.
          • Drug Found To Help Lower Clotting Risk Prior To Cardiac Surgery
            As a potent and reversible platelet inhibitor, cangrelor has been proposed for use in a bridging strategy for patients scheduled for surgery who are currently taking clopidogrel or another thienopyridine. To test this strategy, the BRIDGE investigators randomized 210 ACS or stent patients awaiting CABG and taking a thienopyridine to receive either cangrelor or placebo for at least 48 hours prior ...
          • New Therapy Might Help Relieve Painful Foot Condition
            WEDNESDAY Feb. 8 (HealthDay News) -- For people struggling with plantar fasciitis --- a painful and sometimes disabling foot condition -- a small, preliminary study suggests that a new type of therapy is more effective than standard cortisone injections in restoring mobility.
          • Brookline residents part of ‘Team 20’ platelet donors
            Hillary Glick, Eric Kaye and Mel Stoler of Brookline are three of the more than 80 “Team 20” platelet donors recognized by the Kraft Family Blood Donor Center at Dana-Farber Institute for their donations of blood platelets during the past year.
          • Platelet receptor could help with diseases that impact RBCs
            A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists.
          • Hospitals seek regular platelet donors
            Hospitals say major accidents, like the one that happened in Little River Academy early Tuesday morning, highlight the important need for blood and platelet donors.

               Related on Wikipedia




























           

          Powered free by PHPmotion